Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors-Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

Back to course

Pdf Summary

The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have updated their guidelines for molecular testing in lung cancer patients. The updated guidelines include new recommendations for genetic testing based on advancements in technology and therapies. The guideline emphasizes the need for testing for specific genetic alterations such as EGFR, ALK, and ROS1 in patients with advanced-stage lung adenocarcinoma. It also recommends testing for additional genes such as BRAF, MET, RET, ERBB2, and KRAS using next-generation sequencing panels. The guideline recommends the use of immunohistochemistry as an alternative to fluorescence in situ hybridization for ALK and ROS1 testing. It also suggests using cell-free DNA testing when tissue is limited or hard to obtain. The goal of the updated guidelines is to improve the precision and accuracy of molecular testing in order to guide targeted therapies for lung cancer patients. The guidelines also address the use of targeted therapies, such as EGFR and ALK inhibitors, and provide recommendations for testing patients who have relapsed on targeted therapy. The guidelines stress the importance of testing for these genetic alterations in order to provide optimal care for patients and better understand any limitations of the assays used for testing. The guidelines also acknowledge the need for further research on the use of immunomodulatory therapies and the development of standardized assays for biomarker testing in lung cancer. The authors of the guidelines disclose potential conflicts of interest but state that these relationships did not influence the development of the guidelines. Overall, the updated guidelines provide evidence-based recommendations for molecular testing in lung cancer patients and aim to improve patient outcomes through personalized treatment approaches.

Asset Subtitle

Guideline From the College of American Pathologists,
the International Association for the Study of Lung Cancer, and
the Association for Molecular Pathology

Keywords

molecular testing

lung cancer patients

genetic testing

EGFR

ALK

ROS1

next-generation sequencing panels

immunohistochemistry

targeted therapies

biomarker testing